Asahi Kasei Pharma, a global pharmaceutical company, is seeking preclinical drug candidates for specific transplant complications with demonstrated in vitro efficacy, ideally supported by in vivo data. 
Approaches of Interest:
<ul>
<li>High priority indications include transplant rejection, antibody-mediated rejection, delayed graft function, post-transplant lymphoproliferative disorder, transplant-associated thrombotic microangiopathy, chronic lung allograft dysfunction, cardiac allograft vaculopathy, whereas graft-versus-host disease is considered a lower priority </li>
<li>Open to biologics, small molecules, peptides and RNA-based approaches</li>
<li>Novel drug candidates that are intended for use in combination with existing drugs are within scope </li>
</ul>
Out of Scope:
<ul>
<li>Drug repurposing </li>
<li>Cell therapy, probiotics, gene editing and AAV therapy </li>
<li>Diagnostic products, medical devices, platform technologies, drug screening libraries </li>
<li>Opportunities that focus solely on understanding mechanisms or exploring new targets </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities from preclinical research phase to late preclinical research stage are within scope, provided the efficacy has been confirmed in an in vitro study reflecting the treatment concept </li>
<li>It is desirable that the effectiveness has been confirmed in an in vivo study using an animal model of a transplant related target indication </li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions must include details on both the indication and the stage of development of the opportunity. Please provide this information using this <a href="">submission form</a>. If not provided, we may request this information before your submission is accepted. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, and research collaborations.

Asahi Kasei Pharma is actively seeking preclinical drug candidates targeting specific transplant-related complications, including transplant rejection and antibody-mediated rejection, with demonstrated in vitro efficacy.



Seeking Drug Candidates to Address Transplant-related Complications 

A global health company is seeking manufacturers that specialize in advanced drug delivery systems, specifically, pre-fillable syringes (PFS) and autoinjectors. The team is searching for solutions that enhance safety, improve medication adherence and compliance, and streamline the drug administration process across a wide range of therapeutic areas. 
<h3>Approaches of Interest:</h3>
<ul>
<li>Autoinjectors and pre-fillable syringes of all specifications are of interest (e.g. needle size, dose volume, etc.) </li>
<li>All syringe materials are of interest (e.g. glass, polymers, etc.) </li>
<li>The solutions and manufacturers should meet the strictest global regulatory and highest production standards </li>
</ul>
<h3>Out of Scope:</h3>
<ul>
<li>Companies/solutions for only filling pre-made syringes or autoinjectors (without manufacturing capability). Manufacture and filling in one company/process is within scope. </li>
</ul>
<h3>Developmental Stages of Interest:</h3>
<ul>
<li>Solutions with current manufacturing capability at scale are of interest </li>
<li>Novel developments/proof of concepts which show promise as future solutions in syringes/autoinfection are also of interest, but not prioritised in this campaign </li>
</ul>
<h3>Submission Information</h3>
Submission of 200–300-word briefs is encouraged, including a description of the company and manufacturing capabilities. Supplementary information e.g. company websites, relevant publications or slide decks can be provided as attachments. 
This campaign is primarily open to submissions from companies, including CMOs, with expertise and manufacturing capabilities in this field. Submissions from spinouts and start-ups/SMEs with relevant capabilities or novel developments in this area may also be considered. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
<h3>Opportunity for Collaboration</h3>
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis.

A global health company is seeking manufacturers that specialize in pre-fillable syringes and autoinjectors that meet strict global regulatory and high production standards.

Seeking Manufacturers Specializing in Pre-fillable Syringes (PFS) and Autoinjectors

PDI, a global infection prevention company, is seeking novel sporicidal surface disinfectants that kill the Clostridioides difficile bacteria. The team is specifically interested in solutions that act quickly against C. difficile. The disinfectants should have little to no scent and be suitable for use in a clinical environment. 
<h3>Approaches of Interest: </h3>
<ul>
<li>Surface disinfectants that kill a broad spectrum of bacteria and viruses are desired, with a focus on efficacy against C. difficile</li>
<li>Solutions should be cost effective, have a low toxicity profile, and not cause irritation to the skin, eyes, or respiratory system </li>
<li>Formulations that reduce or eliminate the odor of existing sporicidal disinfectants without reducing efficacy against C. difficile are in scope or the formula itself should have very little to no scent </li>
<li>Solutions that offer a more sustainable alternative to current disinfectants are desirable </li>
</ul>
<h3>Out of Scope: </h3>
<ul>
<li>Surface disinfectants with a strong odor </li>
</ul>
<h3>Developmental Stages of Interest: </h3>
<ul>
<li>Opportunities that have validation in a relevant environment (TRL 5) onwards are in scope </li>
</ul>
<h3>Submission Information </h3>
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Including an outline of how your solution is cost effective in the current landscape is also encouraged. This campaign is open to submissions from SMEs and start-up companies. In submitting to this campaign, you confirm that your submission contains only non-confidential information. 
<h3>Opportunity for Collaboration </h3>
Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, purchasing of assets, and co-development.

PDI is seeking sporicidal surface disinfectants with little to no scent that effectively kill Clostridioides difficile.

Novel Sporicidal Disinfectants Without Scent

A top five pharmaceutical company is seeking novel approaches and emerging science targeting neuro-immune crosstalk, to promote deep healing and sustained response in autoimmune and inflammatory diseases. Approaches should complement or surpass existing anti-inflammatory treatments. Solutions that target multiple nodes or pathways in a disease to return tissue(s) to homeostasis are of high interest. 
Approaches of Interest:
<ul>
<li>Novel therapeutic approaches to reset the immune system in inflammatory diseases including Rheumatoid Arthritis; Psoriatic Arthritis; Ankylosing Spondylitis; Sjogren Disease; Systemic Lupus Erythematosus; Atopic Dermatitis; Psoriasis; Crohn’s Disease; Ulcerative Colitis; Asthma; Chronic Obstructive Pulmonary Disease; Hidradenitis Suppurativa </li>
<li>Targeting neural anti-inflammatory pathways to return tissues to homeostasis, promote wound healing, or polarisation of cells to promote tolerance and resolve inflammation </li>
<li>Approaches of interest include neuropeptides (CGRP, SP, etc); neurotransmitters (GABA, acetylcholine, etc); enteric neurons; enteric nervous system; vagal and sympathetic innervation of the gastrointestinal tract; intrinsic primary afferent neurons (IPANs); vasoactive intestinal peptide (VIP) neurons; cholinergic neurons; enteric Glial Cells (EGC); regulatory MoAs in immune cells (adaptive and innate), epithelial and stromal cells (fibroblasts, etc.)</li>
<li>Therapeutic discovery or development platforms may be considered if specific to neuro‑immune pathways</li>
</ul>
Out of Scope:
<ul>
<li>Therapies causing broad immune suppression </li>
<li>Microbiome-targeted approaches (e.g. probiotics), neurodegenerative disease </li>
<li>Gene therapy, cell therapy, medical devices, device-mediated drug delivery approaches, biomarkers (without intervention/therapeutic), and drug repurposing </li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Therapeutics should have pre-clinical validation, with preference for human cell systems and in vivo model data</li>
<li>Submissions from companies, institutes, or researchers with proven track record in the relevant disease areas are welcome, preferably with suggested next steps to advance solutions in this area </li>
</ul>
Submission Information and Opportunity for Collaboration
Submissions should contain 200–300-word briefs along with any relevant data and supplementary information e.g., relevant publications, slide decks and patents. In submitting to this campaign, you confirm and acknowledge that your submission (i) contains only non-confidential information, (ii) creates no obligation of confidentiality (or any other obligation) on any recipient, and (iii) does not infringe or misappropriate any third-party rights. 
Our client is open to a range of potential collaboration opportunities, with the most appropriate outcome being decided in their sole discretion and on a case-by-case basis. Example outcomes may include licensing, investment and research collaborations.

A top five pharmaceutical company seeks research targeting neural anti-inflammatory pathways to restore tissue homeostasis in inflammatory diseases.

Seeking Novel Approaches to Promote Immune Reset in Inflammatory Disease/Autoimmune Conditions by Targeting Neuro-Immune Crosstalk  

No7 Beauty Company, a subsidiary of Walgreens Boots Alliance, is seeking partnerships in skin health, with a focus on advancing methods to monitor senescence, energetic state, and epigenetics. 
Approaches of Interest:
<ul>
<li>Key areas of interest in energetic state include: (i) mitochondrial aging and its impact on skin cell performance; (ii) approaches to treating mitochondrial dysfunction; (iii) assessment of key markers like NADH; (iv) establishing a causal link between cellular energy production and skin performance, such as extracellular matrix production</li>
<li>Key areas of interest in senescence include: (i) methods to classify cells as senescent or healthy across in vitro, ex vivo, and in vivo models; (ii) research into senescence triggers and tissue progression; (iii) the impact of senescent cells on surrounding healthy cells; (iv) technologies for senescence prevention, including senolytics and senomorphics </li>
<li>Key areas of interest for epigenetics include: (i) research into the epigenetic changes in skin which drive ageing and the associate phenotypic changes; (ii) development of skin specific epigenetic clocks that identify methylation changes relating to environmental exposures in particular UV</li>
<li>In vivo diagnostics that can provide senescence, epigenetic or cellular energetic profiles for intervention recommendations or product benefit demonstration</li>
<li>Active ingredients (e.g., small molecules and peptides), adjunctive therapies (e.g., devices and penetration enhancers) and diagnostic services are of interest</li>
<li>All stages of development are of interest from basic research to registration</li>
<li>Research must include in vitro and/or ex vivo human tissue data (in vivo preferred) showing efficacy vs. industry benchmarks (e.g., Retinol, Vitamin C, Niacinamide), with a clear mechanism of action tied to visible, consumer-relevant skin benefits; projects should be in or moving toward human cell models</li>
</ul>
Out of Scope:
<ul>
<li>Drug repurposing, class III medical devices, late-stage commercial products, and fully developed formulations</li>
<li>Research supported by animal model data only</li>
</ul>
Submission Information and Opportunity for Collaboration
Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. No7 Beauty Company is also open to novel research proposals which can be outlined using this <a href="">submission form</a>. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Our client is open to a range collaboration opportunities, with a primary focus on the United States. The most appropriate outcome will be determined on a case-by-case basis, potentially including licensing assets, project/PhD funding, and research collaborations.

The Walgreens Boots Alliance No7 Beauty Company is seeking partnerships in skin health, with a focus on advancing methods to monitor senescence, energetic state, and epigenetics. 

Innovations in Senescence and Cellular Energetics for Optimizing Skin Health

Cumulus Oncology is seeking small molecule oncology assets that are at or near the IND-enabling stage and supported by GLP toxicology data, a defined biomarker strategy, and has potentially started GMP synthesis. In particular, their goal is to identify programs with strong translational relevance and a clear path to early clinical proof of concept.
Approaches of Interest:
<ul>
<li>Ideal assets will have a well-characterized mechanism of action and potential for monotherapy or rational combinations</li>
<li>Assets with defined biomarkers to support patient selection will be prioritized </li>
<li>Assets attracted to targets that have multi-indication potential are of interest – for example, inflammation-driven cancer pathways </li>
<li>Small molecule assets are of highest interest </li>
</ul>
Out of Scope:
<ul>
<li>Diagnostic‑only approaches</li>
</ul>
Developmental Stages of Interest:
<ul>
<li>Opportunities from late preclinical research stage to Phase I stage are within scope. Opportunities that involve novel targets and demonstrate in vivo efficacy in solid tumor models.</li>
</ul>
Submission Information
Submission of one-page, 200–300-word briefs are encouraged, along with any optional supplementary information e.g., relevant publications. Submissions from academic institutes must be supported by GLP toxicology data. In submitting to this campaign, you confirm that your submission contains only non-confidential information.
Opportunity for Collaboration
Our client is open to a range of collaboration opportunities, where any of: partnership (co-funding), licensing and asset purchase are options. Collaboration terms will be tailored on a case-by-case basis based on asset maturity, strategic alignment, and development potential.

Cumulus Oncology is seeking small molecule oncology assets that are at or near the IND-enabling stage, with a preference for those supported by GLP toxicology and a biomarker strategy.

Engage with world leading R&D teams

Active campaigns

ico

Seeking Drug Candidates to Address Transplant-related Complications

Previous campaigns

ico

Seeking Manufacturers Specializing in Pre-fillable Syringes (PFS) and Autoinjectors

ico

Novel Sporicidal Disinfectants Without Scent

ico

Seeking Novel Approaches to Promote Immune Reset in Inflammatory Disease/Autoimmune Conditions by Targeting Neuro-Immune Crosstalk

ico

Innovations in Senescence and Cellular Energetics for Optimizing Skin Health

ico

Seeking Late Preclinical Oncology Assets: Small Molecules with IND-enabling Data and Patient Stratification Potential

Trusted by